CurifyLabs, a Finnish health technology company, closed a $14mn Series A round to expand its US business and advance personalized medicine manufacturing.
Sandwater and HealthCap led the financing. Tesi, Finnish Industry Investment, joined existing investors including Lifeline Ventures. US customers and CurifyLabs employees also invested in the round, according to Beinsure.
The company will use the proceeds to expand US operations. Funding will strengthen supply-chain infrastructure and improve customer support. CurifyLabs will also accelerate product development.
Founded in 2021, CurifyLabs develops systems for automated pharmaceutical compounding. Its Compounding System Solution, or CSS, combines proprietary software with GMP-manufactured excipient bases. Advanced 3D printing completes the process.
The CSS automates the preparation of patient-specific medicines. Built-in quality-control processes support tailored doses and dosage forms.
CurifyLabs says pharmacies achieve greater precision and speed than traditional manual compounding methods offer.
Pharmacies across 21 US states use the technology. European pharmacy partners also compound and dispense thousands of doses each day through the platform.
CurifyLabs plans deeper supply-chain investment as its partner base grows. The company aims to ensure pharmacies receive necessary products when demand arises, without bottlenecks or dead stock.
Sandwater partner Morten E. Iversen said personalized medicine ranks among healthcare’s important areas for improved patient outcomes. He said the segment continues to grow, with pharmacy teams seeking safer and more efficient production methods.
Personalized medicine is one of the most important frontiers in healthcare enabling better patient outcomes and is experiencing solid growth. We are enabling more pharmacies to deliver personalized medicine in a safer and more efficient way
Morten E. Iversen, partner at Sandwater
Iversen said CurifyLabs combines clinical rigor with practical speed and precision for pharmacy staff. Sandwater expects to support the company’s growth in the US and other markets.
“CurifyLabs has built something rare – technology that combines clinical rigor with the speed and precision that busy pharmacy teams depend on. We are excited to support their rapid growth in the U.S. and beyond”, Morten E. Iversen says.
- HealthCap partner Daniel Karsberg said the firm has backed more than 136 life sciences companies over nearly three decades. He said strong founders pair scientific depth with consistent real-world execution, and CurifyLabs fits this profile.
- Tesi Investment Director Joni Karsikas said the company brings scientific expertise and international ambitions. He described US growth as evidence of Finnish health technology competing successfully in overseas markets.
- Charlotta Topelius, CurifyLabs founder and CEO, said the funding reflects partner confidence in the company’s work. She said CurifyLabs maintains high standards for clinical rigor, product quality and customer support.
The company will continue development of its platform, including the PharmaPrinter Aurum. CurifyLabs says Aurum compounds medicines up to nine times faster than manual pharmacy processes.
The technology holds ISO 13485 certification. CurifyLabs designed its platform for compliance with FDA 503A and 503B standards governing non-sterile compounding.
According to Beinsure, the Series A gives CurifyLabs fresh capital for US expansion at a point when personalized therapies require more scalable pharmacy production.
HealthCap invests exclusively in life sciences and operates from Stockholm and Lausanne. Founded in 1996, the firm has raised more than €1.5bn across 10 funds and supported more than 36 companies globally.
Tesi operates as a state-owned Finnish investment company. It invests on market terms in venture capital funds, private-equity funds and growth companies, with a mandate to develop Finland’s investment market and support economic growth.
